Currency In USD
| Previous Close | 8.24 |
| Open | 8.38 |
| Day High | 8.49 |
| Day Low | 7.96 |
| 52-Week High | 20.56 |
| 52-Week Low | 7.12 |
| Volume | 1.47M |
| Average Volume | 482,627 |
| Market Cap | 150.45M |
| PE | -1.31 |
| EPS | -6.19 |
| Moving Average 50 Days | 9.73 |
| Moving Average 200 Days | 9.23 |
| Change | -0.12 |
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will presen
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 12:30 PM GMT
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will presen
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of